natgillin/translations-raw huggingface dataset:
For the mobilisation of PBPC in patients undergoing myelosuppressive or myeloablative therapy followed by autologous peripheral blood progenitor cell transplantation
Za mobilizaciju progenitorskih stanica periferne krvi u bolesnika s presađenim autolognim progenitorskim stanicama periferne krvi nakon mijelosupresijske ili mijeloablacijske terapije
9/L, and a history of severe or recurrent infections, long absolute neutrophil count (ANC) of ≤ 0.5 x 10 term administration of Biograstim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.
U bolesnika, djece i odraslih, s teškom kongenitalnom cikličkom ili idiopatskom neutropenijom i apsolutnim brojem neutrofila (ABN) ≤ 0,5 x 109/l, kao i s teškim ili rekurentnim infekcijama u anamnezi, dugotrajna primjena Biograstim se koristi za povećanje broja neutrofila i za smanjenje incidencije i skraćivanje trajanja događaja povezanih s infekcijama.
Isolated cases of sickle cells crises have been reported in patients with sickle cell disease (see section 4.4).
U bolesnika s anemijom srpastih stanica (vidjeti dio 4.4) prijavljeni su izolirani slučajevi kriza srpastih stanica.
- The active substance is filgrastim.
Što Biograstim sadrži - Djelatna tvar je filgrastim.
Elevated alkaline phosphatase, elevated LDH, elevated uric acid
Povišena alkalna fosfataza, povišena LDH, povišena mokraćna kiselina
For infusions, filgrastim should be diluted in 20 mL of glucose 50 mg/mL (5 %) solution for infusion (see section 6.6 for instructions on dilution).
Za infuziju je filgrastim potrebno razrijediti u 20 ml 50 mg/ml (5 %) otopine glukoze za infuziju (za upute o razrjeđivanju vidjeti dio 6.6).
Established cytotoxic chemotherapy
Utvrđeni protokol citotoksične kemoterapije
The most commonly reported undesirable effect was mild to moderate transient musculo-skeletal pain.
Najčešće prijavljivana nuspojava bila je blaga do umjerena, prolazna bol u mišićno-koštanom sustavu.
Talk to your doctor or nurse that you are treated with Biograstim if you are undergoing bone-imaging.
U slučaju snimanja kostiju recite liječniku ili medicinskoj sestri da se liječite Biograstimom.
Biograstim 30 MIU/0.5 mL solution for injection or infusion Filgrastim
Biograstim 30 MIU/0,5 ml otopina za injekciju ili infuziju filgrastim
Subcutaneous use and intravenous use.
Za potkožnu primjenu i primjenu u venu.
Packs containing 1, 5 or 10 pre-filled syringes with 0.5 mL solution or multipacks containing 10 (2 packs of 5) pre-filled syringes with 0.5 mL solution.
Pakiranje sadrži 1, 5 ili 10 napunjenih štrcaljki s 0,5 ml otopine ili višestruka pakiranja s 10 (2 pakiranja od 5) napunjenih štrcaljki s 0,5 ml otopine.
The use of filgrastim-mobilised PBPCs has been shown to reduce the depth and duration of thrombocytopenia following myelosuppressive or myeloablative chemotherapy.
Pokazalo se da progenitorske stanice periferne krvi, mobilizirane filgrastimom, smanjuju jačinu i skraćuju trajanje trombocitopenije nakon mijelosupresijske ili mijeloablacijske kemoterapije.
Special precautions in sickle cell disease
Posebne mjere opreza pri bolesti srpastih stanica
Packs containing 1, 5 or 10 pre-filled syringes with 0.8 mL solution or multipacks containing 10 (2 packs of 5) pre-filled syringes with 0.8 mL solution.
Pakiranje sadrži 1, 5 ili 10 napunjenih štrcaljki s 0,8 ml otopine ili višestruka pakiranja s 10 (2 pakiranja od 5) napunjenih štrcaljki s 0,5 ml otopine.
EU/1/08/450/001 1 pre-filled syringe EU/1/08/450/002 5 pre-filled syringes EU/1/08/450/004 10 pre-filled syringes EU/1/08/450/009 5 pre-filled syringes with safety device
EU/1/08/450/001 1 napunjena štrcaljka EU/1/08/450/002 5 napunjenih štrcaljki EU/1/08/450/004 10 napunjenih štrcaljki EU/1/08/450/009 5 napunjenih štrcaljki sa zaštitom za iglu
Haematuria/proteinuria occurred in a small number of patients.
U malog broja bolesnika javila se hematurija/proteinurija.
9/L during the treatment period the dose of filgrastim should be reescalated according to the above steps
Smanji li se ABN tijekom trajanja terapije na < 1,0 x 109/l, dozu filgrastima treba ponovno povećavati u skladu s gornjom shemom.
Daily dosing with filgrastim should continue until the expected neutrophil nadir is passed and the neutrophil count has recovered to the normal range.
Filgrastim treba davati svakodnevno, sve dok ne prođe razdoblje očekivanih najnižih vrijednosti broja neutrofila i dok se njihov broj ne normalizira.
cannot be estimated from the available data Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
U svakoj skupini prema učestalosti, nuspojave su navedene silaznim slijedom prema ozbiljnosti.
However, in view of the potential risks associated with severe leukocytosis, a white blood cell count should be performed at regular intervals
No sa stajališta mogućih rizika povezanih s jakom leukocitozom, pri terapiji filgrastimom potrebno je u redovitim vremenskim razmacima, provjeravati broj leukocita.
In normal stem cell donors
U zdravih davatelja matičnih stanica
9/L) was observed in 41 % of donors and transient 9/L) following filgrastim and leukapheresis was observed in thrombocytopenia (platelets < 100 x 10
Leukocitoza (leukociti > 50 x 109/l) je uočena u 41 %, a prolazna trombocitopenija (trombociti < 100 x 109/l) u 35 % davatelja nakon primjene filgrastima i leukafereze.
Sixty-five percent of the patients studied in the SCN trial programme were under 18 years of age.
Pedijatrijska primjena u bolesnika s teškom kroničnom neutropenijom i u onkoloških bolesnika Šezdeset pet posto bolesnika uključenih u program ispitivanja teške kronične neutropenije bilo je mlađe od 18 godina.
Special precautions in normal donors undergoing peripheral blood progenitor cell mobilisation
Posebne mjere opreza u zdravih davatelja u kojih se obavlja mobilizacija progenitorskih stanica periferne krvi
EU/1/08/450/005 1 pre-filled syringe EU/1/08/450/006 5 pre-filled syringes EU/1/08/450/008 10 pre-filled syringes EU/1/08/450/010 5 pre-filled syringes with safety device
EU/1/08/450/005 1 napunjena štrcaljka EU/1/08/450/006 5 napunjenih štrcaljki EU/1/08/450/008 10 napunjenih štrcaljki EU/1/08/450/010 5 napunjenih štrcaljki sa zaštitom za iglu
Vascular disorders, including veno-occlusive disease and fluid volume disturbances, have been reported occasionally in patients undergoing high dose chemotherapy followed by autologous bone marrow transplantation.
U bolesnika kojima je presađena koštana srž nakon prethodne primjene velikih doza kemoterapije bilo je povremenih prijava poremećaja krvnih žila, uključujući venookluzivnu bolest i poremećaje volumena tekućine.
Dispose of syringes with safety device as instructed by your doctor, nurse or pharmacist.
Štrcaljku zbrinite kako su Vam objasnili liječnik, medicinska sestra ili ljekarnik.
Biograstim 48 MIU/0.8 mL solution for injection or infusion Filgrastim
Biograstim 48 MIU/0,8 ml otopina za injekciju ili infuziju filgrastim
Box for the prescribed dose
Prostor za preporučeno doziranje
Allergic Reactions: Allergic-type reactions, including anaphylaxis, skin rash, urticaria, angioedema, dyspnoea and hypotension, occurring on initial or subsequent treatment, have been reported in patients receiving filgrastim.
Alergijske reakcije: U bolesnika koji su primali filgrastim prijavljivane su alergijske reakcije na početku primjene ili pri kasnijoj primjeni, uključujući anafilaksiju, kožni osip, urtikariju, angioedem, dispneju i hipotenziju.
Special precautions in patients undergoing peripheral blood progenitor cell mobilisation Mobilisation
Posebne mjere opreza u bolesnika u kojih se obavlja mobilizacija progenitorskih stanica periferne krvi
Transient cytogenic modifications have been observed in normal donors following G-CSF use.
U zdravih davatelja koji su primali G-CSF uočene su prolazne citogenetske promjene.
Solution for injection or infusion Multipack: 10 (2 packs of 5) pre-filled syringes containing 0.8 mL.
Višestruko pakiranje: 10 (2 pakiranja od 5) napunjenih štrcaljki koje sadrže 0,8 ml.
Alopecia, skin rash Sweet's syndrome, cutaneous vasculitis
Sweetov sindrom, kožni vaskulitis
Each mL of solution for injection or infusion contains 60 million international units [MIU] (600 µg) of filgrastim.
KVALITATIVNI I KVANTITATIVNI SASTAV Jedan ml otopine za injekciju ili infuziju sadrži 60 milijuna internacionalnih jedinica [MIU] (600 μg) filgrastima.
The following undesirable effects and their frequencies have been observed under treatment with filgrastim based on published information.
Nuspojave prema dosad objavljenim podacima, i njihova učestalost pri primjeni filgrastima niže su navedene.
The duration of fever was not reduced in patients undergoing myeloablative therapy followed by bone marrow transplantation.
U bolesnika kojima je nakon mijeloablacijske terapije presađena koštana srž nije se skratilo vrijeme trajanja vrućice.
No effect was observed on the fertility of male and female rats or gestation in rats.
Filgrastim se nije pokazao teratogenim u štakora i kunića.
Solution for injection or infusion Multipack: 10 (2 packs of 5) pre-filled syringes containing 0.5 mL.
Višestruko pakiranje: 10 (2 pakiranja od 5) napunjenih štrcaljki koje sadrže 0,5 ml.
When the response has been obtained, the reached and can be maintained at more than 1.5 x 10 minimal effective dose to maintain this level should be established.
Nakon što se postigne odgovor, treba odrediti minimalnu učinkovitu dozu za održavanje te razine neutrofila.
Biograstim 30 MIU/0.5 mL solution for injection or infusion
NAZIV LIJEKA Biograstim 30 MIU/0,5 ml otopina za injekciju ili infuziju
Subsequently the dose may be
OD LIJEKA AKO JE POTREBNO
2/day (4.0 to 8.4 μg/kg/day) was used.
U randomiziranim kliničkim ispitivanjima davala se supkutano doza od 23 MIU (230 μg)/m2/dan (4,0 do 8,4 μg/kg/dan).
During long term use, cutaneous vasculitis has been reported in 2 % of SCN patients.
Tijekom dugotrajne primjene u 2 % bolesnika s teškom kroničnom neutropenijom prijavljen je vaskulitis.
Contents of the pack and other information What Biograstim contains
Sadržaj pakiranja i druge informacije
A faster schedule of dose escalation may be considered in patients presenting with and 10 x 10 severe infections.
U bolesnika s teškim infekcijama može se razmotriti brže prilagođavanje doze.
Exacerbation of rheumatoid arthritis has been observed in individual cases.
Bilo je pojedinačnih slučajeva egzacerbacije reumatoidnog artritisa.
In patients treated with myeloablative therapy followed by bone marrow transplantation
Bolesnici s presađenom koštanom srži i prethodnom mijeloablacijskom terapijom
Very rare (may affect up to 1 in 10,000 people): - painful, raised, plum-coloured sores on the limbs and sometimes the face and neck with fever
Rijetko (mogu se javiti do 1 na 1000 osoba): - vaskularni poremećaji, koji mogu uzrokovati bol, crvenilo i oticanje udova.
There was a low frequency (approximately 3 %) of myelodysplastic syndromes (MDS) or leukaemia in clinical trial patients with SCN treated with filgrastim.
U kliničkim ispitivanjima bolesnika s teškom kroničnom neutropenijom koji su primali filgrastim, malom su se učestalošću (oko 3 %) javljali mijelodisplastični sindrom (MDS) ili leukemija.
Consideration should be given to intermittent cessation or decreasing the dose of filgrastim in patients who develop thrombocytopenia, i.e. platelets consistently < 100,000/mm
U bolesnika koji razviju trombocitopeniju, tj. kada je broj trombocita kontinuirano < 100 000/mm3, potrebno je razmotriti mogućnost povremenih prekida primjene ili smanjenja doze filgrastima.
(Sweet's syndrome); inflammation of blood vessels, often with skin rash; - worsening of rheumatic conditions; - pains or difficulties in passing urine.
- pojava bolnih, uzdignutih, modro obojenih žarišta po udovima te katkada i po licu i vratu praćenih vrućicom (Sweetov sindrom); upala krvnih žila, često uz kožni osip; - pogoršanje reumatskih stanja; - bolno ili otežano mokrenje.
Treatment with filgrastim alone does not preclude thrombocytopenia and anaemia due to myelosuppressive medicinal products.
Rizik povezan s povećanim dozama mijelosupresijskih lijekova Primjena filgrastima samog ne znači da će se spriječiti pojava trombocitopenije i anemije izazvana primjenom mijelosupresijskih lijekova.
Biograstim 48 MIU/0.8 mL solution for injection or infusion
NAZIV LIJEKA Biograstim 48 MIU /0,8 ml otopina za injekciju ili infuziju
These autologous PBPCs may be harvested and infused after high-dose cytotoxic therapy, either in place of or in addition to bone marrow transplantation.
Autologne progenitorske stanice periferne krvi mogu se izdvojiti, i ponovno dati infuzijom nakon velikih doza citotoksične kemoterapije, bilo umjesto presađivanja koštane srži, bilo zajedno s njim.
SPECIAL STORAGE CONDITIONS
Posebne populacije
Rare:
Rijetko
Filgrastim
Proljev
Spleen disorder
Poremećaj slezene
Long-term daily administration is required to maintain an adequate neutrophil count.
Za održavanje primjerenog broja neutrofila nužna je dugotrajna primjena lijeka.
In peripheral blood progenitor cell mobilisation in normal donors
Pri mobilizaciji progenitorskih stanica u perifernoj krvi zdravih davatelja
Leukocytosis, thrombocytopenia Spleen disorder
Leukocitoza, trombocitopenija
Solution for injection or infusion 5 pre-filled syringes containing 0.8 mL.
5 napunjenih štrcaljki koje sadrže 0,8 ml.
Biograstim and peripheral blood stem cell mobilisation If you are donating stem cells for yourself, the usual dose is 0.5 million to 1 million international units (MIU) per kilogram bodyweight each day.
Ako ćete primiti vlastite matične stanice, uobičajena doza je 0,5 milijuna do 1 milijun internacionalnih jedinica [MIU] po kilogramu tjelesne težine na dan.
≥ 1/1,000 to < 1/100
≥1/100 do <1/10, Manje česte: ≥1/1000 do <1/100, Rijetke:
EU/1/08/450/007 2 x 5 pre-filled syringes
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/08/450/007 2 x 5 napunjenih štrcaljki
cells/kg is based on published experience resulting in adequate haematologic reconstitution.
Preporuka o minimalnom prinosu od 2,0 x 106 CD34+ stanica/kg temelji se na dosad objavljenim iskustvima, u kojima se postigla primjerena hematološka rekonstitucija.
Excipients
Učestalost
In severe chronic neutropenia patients
Bolesnici s teškom kroničnom neutropenijom
Solution for injection or infusion 5 pre-filled syringes containing 0.5 mL.
5 napunjenih štrcaljki koje sadrže 0,5 ml.
EU/1/08/450/003 2 x 5 pre-filled syringes
12. BROJ(EVI) ODOBRENJA ZA STAVLJANJE LIJEKA U PROMET EU/1/08/450/003 2 x 5 napunjenih štrcaljki
Special precautions in recipients of allogeneic PBPC mobilised with filgrastim
Posebne mjere opreza u primatelja alogeničnih progenitorskih stanica periferne krvi mobiliziranih filgrastimom
Chest pain, musculoskeletal pain
Bol u prsištu, bol u mišićnokoštanom sustavu
In patients with HIV infection For reversal of neutropenia
Bolesnici s HIV-infekcijom
Prior to allogeneic PBPC transplantation, use of filgrastim for the mobilisation of PBPC in normal donors allows a collection of 4 x 10
Primjenom filgrastima u zdravih davatelja u svrhu mobilizacije progenitorskih stanica periferne krvi prije alogenog presađivanja tih stanica, u većine se davatelja dvjema leukaferezama prikupi 4 x 106 CD34+ stanica po kg tjelesne težine davatelja.
Uncommon
Kronični
Then, if ANC remains > 1.0 x 10
Potom, ako je ukupni broj neutrofila >1,0x109/l tijekom najmanje 3 uzastopna dana
Transient, minor increases in alkaline phosphatase, LDH, SGOT (serum glutamic oxaloacetic transaminase) and uric acid have been reported in normal donors receiving filgrastim; these were without clinical sequelae.
U zdravih davatelja koji su primali filgrastim bilo je prijava prolaznog i slabog povišenja alkalne fosfataze, LDH, AST i mokraćne kiseline; to nije imali nikakvih kliničkih posljedica.
6.6 Special precautions for disposal and other handling
4.4 Posebna upozorenja i mjere opreza pri uporabi
4.8 Undesirable effects Summary of the safety profile
Sažetak sigurnosnog profila
Very rare events of cutaneous vasculitis have been reported in patients treated with filgrastim.
U bolesnika koji su primali filgrastim bilo je vrlo rijetkih prijava kožnog vaskulitisa.
Sickle cells crises, in some cases fatal, have been reported with the use of filgrastim in subjects with sickle cell disease.
Pri primjeni filgrastima u bolesnika s anemijom srpastih stanica bilo je prijava kriza srpastih stanica, u nekim slučajevima sa smrtnim ishodom.
Transformation to leukaemia or myelodysplastic syndrome
Nuspojava Leukocitoza, trombocitopenija
Prior exposure to cytotoxic agents
Prethodno liječenje citotoksičnim pripravcima
Special precautions in cancer patients Leukocytosis
Posebne mjere opreza u bolesnika s akutnom mijeloičnom leukemijom
be required to maintain the ANC > 2.0 x 10
Leukaferezu treba obavljati tijekom razdoblja u kojem ABN s < 0,5x109/l poraste na > 5,0 x 109/l.
Sickle cell crisis has happened in some patients with Sickle Cell Disease who have been given filgrastim.
U nekih bolesnika s anemijom srpastih stanica, koji su uzimali filgrastim, javila se kriza srpastih stanica.
Thrombocytopenia
Leukocitoza
Method of administration
NAČIN PRIMJENE LIJEKA
In SCN patients
U onkoloških bolesnika
Information for injecting yourself
Informacije za samostalnu primjenu lijeka
Your doctor will decide how many days treatment is needed.
Vaš liječnik će odlučiti koliko dana liječenja je potrebno.
In this situation, you should inform your doctor as soon as possible.
U toj situaciji morate što prije obavijestiti svojeg liječnika.
Each infusion will last about an hour.
Svaka infuzija će trajati oko jedan sat.
• If you are a child or growing adolescent below 18 years of age.
• ako ste dijete ili adolescent koji raste mlađi od 18 godina.
Resistant (R >)
Rezistentan (R >)
50131 Florence
50131 Firenca
Other types of skin infections have not been studied.
Nisu ispitivane druge vrste kožnih infekcija.
The total duration of treatment is 5 to 14 days.
Ukupno trajanje liječenja je 5 do 14 dana.
These adverse reactions may occur following the first dose.
Ove se nuspojave mogu pojaviti nakon prve doze.
There are no significant circulating metabolites (mean=9.6%) in humans.
Nema značajnih cirkulirajućih metabolita (srednja vrijednost=9,6%) u ljudi.
• Hearing things that do not exist (auditory hallucination)
• čujenje zvukova koji ne postoje (slušne halucinacije)
If less than 8 hours remain before the next dose, wait until the next scheduled dose.
Ako je do sljedeće doze ostalo manje od 8 sati, tada pričekajte do sljedeće planirane doze.
Children or growing adolescents below 18 years of age (see section 4.2).
Djeca ili adolescenti koji rastu mlađi od 18 godina (vidjeti dio 4.2).
• Decreased appetite
• smanjeni apetit
It is available in packs containing 10 vials.
Dostupan je u pakiranju koje sadrži 10 bočica.
• If you are pregnant, might become pregnant, or think you might be pregnant.
• ako ste trudni, mogli biste zatrudnjeti ili mislite da biste mogli biti trudni.
• Ringing or buzzing in the ears (tinnitus)
• zvonjava ili šum u ušima (tinitus)
In those cases your doctor will consider if this treatment is the best option for you.
Liječnik će u tim slučajevima razmotriti je li ovo liječenje najbolje rješenje za Vas.
Gram-positive micro-organisms:
Gram-pozitivni mikroorganizmi:
EU/1/19/1393/002 10 x 1 tablets EU/1/19/1393/003 20 x 1 tablets EU/1/19/1393/004 30 x 1 tablets EU/1/19/1393/005 50 x 1 tablets EU/1/19/1393/006 60 x 1 tablets EU/1/19/1393/007 100 x 1 tablets
EU/1/19/1393/002 10 x 1 tableta EU/1/19/1393/003 20 x 1 tableta EU/1/19/1393/004 30 x 1 tableta EU/1/19/1393/005 50 x 1 tableta EU/1/19/1393/006 60 x 1 tableta EU/1/19/1393/007 100 x 1 tableta
AlfaSigma 1 Via Enrico Fermi 65020 Alanno (PE) Italy
AlfaSigma 1 Via Enrico Fermi 65020 Alanno (PE) Italija
Quofenix tablets should be taken at least 2 hours before or 6 hours after:
Quofenix tablete treba uzeti najmanje 2 sata prije ili 6 sati nakon:
Do not drive, operate machinery, or do other activities that require mental alertness or coordination until you know how Quofenix affects you.
Nemojte voziti, upravljati strojevima ili sudjelovati u drugim aktivnostima koje zahtijevaju mentalnu pozornost ili koordinaciju dok ne znate kakav učinak Quofenix ima na Vas.
Unchanged parent drug is the predominant component in plasma.
Nepromijenjeni izvorni lijek je dominantna komponenta u plazmi.
If you miss a dose, you should take it as soon as possible anytime up to 8 hours prior to the next scheduled dose.
Ako propustite dozu, trebate je uzeti čim prije moguće, u bilo koje vrijeme najkasnije do 8 sati prije sljedeće planirane doze.
This medicine must not be used in children and adolescents as it has not been studied enough in these groups.
Ovaj lijek se ne smije primjenjivati u djece i adolescenata jer nije dovoljno ispitivan u tim skupinama.
• You had sometimes long treatment with antibiotics; it can mean that you get another infection caused by other bacteria (superinfection) which cannot be treated by the antibiotic.
• ako ste bili dugotrajno liječeni antibioticima; to može značiti da ćete dobiti drugu infekciju uzrokovanu drugom bakterijom (superinfekcija) koja ne može biti liječena tim antibiotikom.
• High blood pressure
• visoki krvni tlak
It belongs to a group of medicines called fluoroquinolones.
Pripada skupini lijekova koji se zovu fluorokinoloni.
These may be signs and symptoms of a hypersensitivity (allergic) reaction and may be life-threatening.
Ovo mogu biti znakovi i simptomi reakcije preosjetljivosti (alergijske reakcije) i mogu biti opasni po život.
Gram-negative micro-organisms:
Gram-negativni mikroorganizmi:
The following information is intended for healthcare professionals only: For single use only.
Sljedeće informacije namijenjene su samo zdravstvenim radnicima:
Frequencies are defined as: very common (≥1/10); common (≥ 1/100 to < 1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).
Učestalosti su definirane kao: vrlo često (≥1/10); često (≥ 1/100 i < 1/10); manje često (≥1/1000 i <1/100); rijetko (≥1/10 000 i
If you stop taking Quofenix without the advice of your doctor, your symptoms may get worse.
Ako prestanete uzimati Quofenix bez savjeta Vašeg liječnika, Vaši simptomi bi se mogli pogoršati.
This medicinal product does not require any special storage conditions if kept unopened in the original container.
Ovaj lijek ne zahtijeva posebne uvjete čuvanja ako je neotvoren i u originalnom spremniku.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8°C, unless reconstitution and dilution has taken place in controlled and validated aseptic conditions.
Ako se ne primijeni odmah, vrijeme i uvjeti čuvanja prije uporabe odgovornost su korisnika te obično ne smiju biti duži od 24 sata na 2 do 8°C, osim ako su rekonstitucija i razrjeđivanje provedeni u kontroliranim i validiranim aseptičkim uvjetima.
If you accidentally take more tablets than you should, tell a doctor or get other medical advice.
Ako slučajno uzmete više tableta nego što ste trebali, obavijestite liječnika ili zatražite drugi medicinski savjet.
• Swollen, red, irritated veins
• otečene, crvene, iritirane vene
Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Potrebno je uzeti u obzir službene smjernice o ispravnoj primjeni antibakterijskih lijekova.
SX Via Morolense 5 03013 Ferentino (FR) Italy or
SX Via Morolense 5 03013 Ferentino (FR) Italija ili
It is used to treat adults with serious short-term infections of the skin and tissues under the skin caused by certain bacteria when usual antibiotics cannot be used or have not worked.
Koristi se za liječenje odraslih s ozbiljnim kratkotrajnim infekcijama kože i tkiva ispod kože uzrokovanih određenim bakterijama kada se uobičajeni antibiotici ne mogu primijeniti ili nisu djelovali.
Contents of the pack and other information What Quofenix contains
Sadržaj pakiranja i druge informacije Što Quofenix sadrži
Injury, poisoning and procedural complications
Ozljede, trovanja i proceduralne komplikacije komplikacija rane
The patient should drink a sufficient amount of fluids while taking Quofenix.
Bolesnik treba piti dovoljno tekućine dok uzima Quofenix.